October 2018
·
33 Reads
·
1 Citation
Health of Man
This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
October 2018
·
33 Reads
·
1 Citation
Health of Man
November 2016
·
23 Reads
·
7 Citations
Obstetrical and Gynecological Survey
(Abstracted from Int Urogynecol J 2016;27:1137–1147) Although the precise pathophysiology of bladder pain syndrome/interstitial cystitis (BPS/IC) is unclear, the underlying mechanism appears related to a defect in the urine-tissue barrier (the bladder’s protective mucous lining of glycosaminoglycans [GAG]). This defect has been documented in a subset of BPS/IC patients, and a favorable response to GAG-restoring agents has been reported.
November 2015
·
295 Reads
·
45 Citations
International Urogynecology Journal
Bladder pain syndrome/interstitial cystitis (BPS/IC) is a chronic disease characterised by persistent irritating micturition symptoms and pain. The objective was to compare the clinical efficacy of currently available products for intravesical therapy of BPS/IC and to assess their pharmacoeconomic impact. A Pubmed/Medline database search was performed for articles on intravesical therapy for BPS/IC. A total of 345 publications were identified, from which 326 were excluded. Statistical evaluation was performed with effect size (ES) assessment of symptom reduction and response rates. The final set of 19 articles on intravesical BPS/IC therapy included 5 prospective controlled trials (CTs), the remaining were classified as uncontrolled clinical studies. The total number of patients included was 801, 228 of whom had been evaluated in a CT. For CTs, the largest ES for symptom reduction as well as response rate was observed for high molecular weight hyaluronic acid (HMW-HA), with similar findings in two uncontrolled studies with HMW-HA. The number needed to treat to achieve a response to intravesical therapy was 2.67 for intravesical pentosan polysulphate and 1.31 for HMW-HA which were superior to all other instillates. HMW-HA was significantly superior in cost effectiveness and cost efficacy to all other instillation regimes. The present meta-analysis combined medical and pharmacoeconomic aspects and demonstrated an advantage of HMW-HA over other instillation agents; however, direct comparisons between the different products have not been performed to date in properly designed controlled studies.
... Studies on the effectiveness of intravesical therapy in patients with BPS/IC have been the subject of five meta-analyses. A detailed analysis of four of them goes beyond the scope of this study, as they consider all options for pharmacological management in BPS/IC [53] or all possible intravesicular treatment options [54][55][56]. The main limitation of these metaanalyses is the very limited number of studies directly comparing different management strategies in patients with BPS/IC, which in turn leads to the risk of erroneous inference from the comparison of absolute results of different studies or network meta-analyses. ...
October 2018
Health of Man
... A meta-analysis of intravesical therapies reported similar response rates for HA, CS and PPS [46]. ...
November 2016
Obstetrical and Gynecological Survey
... Nevertheless, controlled clinical trials concluded that sodium chondroitin sulphate or hyaluronic acid were negative or showed a high recurrence rate during the first year. The exception might be the instillation of high molecular weight hyaluronic acid at a concentration of 0.08 % (99,144). One trial examined the effect of the intravesical instillation of Bacillus Calmétte-Guerin (BCG), although the rationale for BCG instillation, which is used in bladder cancer prevention, remains unclear. ...
November 2015
International Urogynecology Journal